Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $359.41 --0%
EPS Growth %: +22.2%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +22.2%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Public Service Enterprise (PEG) Misses Q3 EPS by 4c ; Offers Guidance
- Regeneron Pharma (REGN) PT Raised to $980 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
